OIA response: Widely dispensed medicines
Data on numbers of patients on the most widely used medicines in New Zealand for 2018 and 2019.
Proposal to award sole supply of infliximab in DHB hospitals
We are proposing to award sole supply of infliximab, a biologic medicine used to treat a range of inflammatory and autoimmune conditions, from 1 September 2020.
Closes: 5pm Wednesday 10 June 2020.
Decision to make changes to funded 60 mm and 56 mm (0.05 mm thickness) male latex condoms
We're pleased to announce a decision to make changes to funded 60 mm nominal width and 56 mm nominal width (0.05 mm thickness) male latex condoms through an agreement with Jackson Allison Medical and Surgical Limited (Jackson Allison).
Atomoxetine – further delay in change of funded brand and open access
PHARMAC is advising all interested parties that there is a further delay in the listing of a new funded brand of atomoxetine and removal of the current funding restrictions. The following reflects the most up-to-date information.
OIA response: Effect of COVID-19 on medicine supply
Information regarding PHARMAC’s response to, and ongoing management of, COVID-19 related pharmaceutical supply issues
Decision to fund pancreatic enzymes modified-release granules (Creon Micro)
We’re pleased to announce a decision to fund pancreatic enzymes modified-release granules (Creon Micro) from 1 June 2020 for the treatment of pancreatic enzyme insufficiency, through an agreement with Mylan New Zealand Limited.
OIA response: Preparations for COVID-19
What has PHARMAC done to mitigate the risk of medical product supply chain disruption for New Zealand’s regular (non pandemic specific) medical product needs.
OIA response: Security of supply of medicines
Request regarding the potential for disruption to the supply of medicines due to the novel coronavirus (COVID-19) outbreak.
OIA Response: Medicines from China
Request for information about medicines and China's role in the supply chain.
OIA response: Vinorelbine
A request for information about brand, supply and use of vinorelbine.
OIA response: Supply of cladribine and dacarbazine
Request about any previous supply issues for cladribine and decarbazine.
OIA response: PrEP Data
Request for data about the number of Special Authority approvals that have been granted for PrEP.
OIA response: Anti-epileptic medicines
Data on the number of females prescribed various epilepsy medicines.
OIA response: New Zealand Pharmaceutical Market
Information about the top 100 medicines prescribed in New Zealand by price and volume.
April 2020 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender, dated 1 November 2019.
Decision to list rehabilitation products supplied by O&M Halyard Limited
We are pleased to announce the approval of a listing agreement for the supply of rehabilitation equipment, patient positioning products and supports with O&M Halyard Limited.
Proposal to list rehabilitation products supplied by Abecca Healthcare Limited and Howard Wright Limited
PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports supplied by Abecca Healthcare Limited and Howard Wright Limited in Part III of Section H of the Pharmaceutical Schedule from 1 July 2020.
Closes: 4pm Wednesday 20 May 2020.
Proposal to list medical devices supplied by Device Technologies New Zealand Limited
PHARMAC is seeking feedback on a proposal to list a range of obstetrics and gynaecology products in Part III of Section H of the Pharmaceutical Schedule from 1 June 2020 through a provisional amendment with Device Technologies New Zealand Limited.
Closes: 4pm Friday 15 May 2020.
Modifying funded access to mifepristone and misoprostol
We are seeking feedback on a proposal to change funded access arrangements to two medicines currently listed on the Pharmaceutical Schedule that are used for medical abortion – mifepristone and misoprostol, noting that misoprostol is unregistered for this indication.
Closes: 5pm Friday 29 May 2020
Decision to list terbutaline sulphate powder for inhalation (Bricanyl Turbuhaler) in a new model of the Turbuhaler device
We are pleased to announce that we have made some changes to the listing of terbutaline sulphate powder for inhalation through an agreement with AstraZeneca.
Newsletters
Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.
Media queries
021 863 342
Media phone is monitored 9am–5pm weekdays
